Cargando…

High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

BACKGROUND: The effective treatment of coronavirus disease 2019 (COVID-19) remains unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in cases of severe COVID-19, but evidence from larger case series is still lacking. METHODS: A multi-center retrospective study was co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Wei, Liu, Xiaosheng, Hong, Ke, Ma, Zhiyong, Zhang, Yuelun, Lin, Ling, Han, Yang, Xiong, Yong, Liu, Zhengyin, Ruan, Lianguo, Li, Taisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933558/ https://www.ncbi.nlm.nih.gov/pubmed/33679771 http://dx.doi.org/10.3389/fimmu.2021.627844

Ejemplares similares

Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
por: Cao, Wei, et al.
Publicado: (2021)

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
por: Cao, Wei, et al.
Publicado: (2020)

Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis
por: Liu, Xiaosheng, et al.
Publicado: (2023)

High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
por: Liu, Xiaosheng, et al.
Publicado: (2020)

Prolonged presence of viral nucleic acid in clinically recovered COVID-19 patients was not associated with effective infectiousness
por: Hong, Ke, et al.
Publicado: (2020)

High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease
por: Hoffmann, Jochen H. O., et al.
Publicado: (2019)

Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study
por: Chen, Yan, et al.
Publicado: (2022)

Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease
por: Danieli, Maria Giovanna, et al.
Publicado: (2021)

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
por: Ahmed, A. Razzaque, et al.
Publicado: (2018)

High-dose intravenous immunoglobulin therapy for novel coronavirus disease 2019: a brief report of two cases
por: Erdogan, Cem, et al.
Publicado: (2020)

Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin
por: Suzuki, Yasuhito, et al.
Publicado: (2020)

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
por: Kato, Hidefumi, et al.
Publicado: (2021)

Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019
por: Sakoulas, George, et al.
Publicado: (2020)

Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury
por: Thom, Vivien, et al.
Publicado: (2017)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Intravenous Immunoglobulin and Immunomodulation of B-Cell – in vitro and in vivo Effects
por: Mitrevski, Milica, et al.
Publicado: (2015)

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
por: Mimura, Yusuke, et al.
Publicado: (2022)

Erratum: Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation
Publicado: (2022)

Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine
por: Diez-Feijóo, Ramon, et al.
Publicado: (2022)

Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications
por: Liu, Yun, et al.
Publicado: (2023)

Case Report: Rheumatoid meningitis with positive NMDAR antibody: A case treated with intravenous immunoglobulin
por: Zhang, Honglian, et al.
Publicado: (2022)

Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin
por: Lion, Julien, et al.
Publicado: (2017)

May early intervention with intravenous immunoglobulin pose a potentially successful treatment for Ebola virus infection?
por: Ge, Ying, et al.
Publicado: (2014)

Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity
por: Kaufman, Gabriel N., et al.
Publicado: (2015)

The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease
por: Pinto, Amelia K., et al.
Publicado: (2021)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
por: Wang, Shang-shang, et al.
Publicado: (2023)

Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin
por: Aljaberi, Rana, et al.
Publicado: (2020)

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
por: Zhang, Wen, et al.
Publicado: (2020)

β-CATENIN stabilizes HIF2 through lncRNA and inhibits intravenous immunoglobulin immunotherapy
por: Nakagawa, Chad, et al.
Publicado: (2023)

Comparative Transcriptional Analysis Identified Characteristic Genes and Patterns in HIV-Infected Immunological Non-Responders
por: Liu, Xiaosheng, et al.
Publicado: (2022)

The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes
por: Tang, Guoxing, et al.
Publicado: (2021)

Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye
por: Tjon, Angela S. W., et al.
Publicado: (2015)

Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
por: Pilon, Caroline, et al.
Publicado: (2020)

Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin
por: Masso-Silva, Jorge Adrian, et al.
Publicado: (2022)

Altered plasma metabolites and inflammatory networks in HIV-1 infected patients with different immunological responses after long-term antiretroviral therapy
por: Lu, Lianfeng, et al.
Publicado: (2023)

Association between tachyarrhythmia and mortality in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19)
por: Gao, Peng, et al.
Publicado: (2021)

Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
por: Galeotti, Caroline, et al.
Publicado: (2020)

High-dose of intravenous immunoglobulin modulates immune tolerance in premature infants
por: Liu, Pin, et al.
Publicado: (2018)

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial
por: Hu, Ke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dag9b6bl2v13keu91492p84j9a